Dataset Information

Ivermectin: a multifaceted drug of Nobel prize-honoured distinction with indicated efficacy against a new global scourge, COVID-19.

ABSTRACT: In 2015, the Nobel Committee for Physiology or Medicine, in its only award for treatments of infectious diseases since six decades prior, honoured the discovery of ivermectin (IVM), a multifaceted drug deployed against some of the world's most devastating tropical diseases. Since March 2020, when IVM was first used against a new global scourge, COVID-19, more than 20 randomized clinical trials (RCTs) have tracked such inpatient and outpatient treatments. Six of seven meta-analyses of IVM treatment RCTs reporting in 2021 found notable reductions in COVID-19 fatalities, with a mean 31% relative risk of mortality vs. controls. During mass IVM treatments in Peru, excess deaths fell by a mean of 74% over 30 days in its ten states with the most extensive treatments. Reductions in deaths correlated with the extent of IVM distributions in all 25 states with p < 0.002. Sharp reductions in morbidity using IVM were also observed in two animal models, of SARS-CoV-2 and a related betacoronavirus. The indicated biological mechanism of IVM, competitive binding with SARS-CoV-2 spike protein, is likely non-epitope specific, possibly yielding full efficacy against emerging viral mutant strains.

SUBMITTER: Santin AD

PROVIDER: S-EPMC8383101 | biostudies-literature |

REPOSITORIES: biostudies-literature

ACCESS DATA

Similar Datasets

Project description:A well-established agenda on the research output, impact, and structure of global scientific elites such as Nobel Prize laureates has generated interest in the scientific elites from developing countries. However, this topic has not been investigated in detail. This study, first, deploys science mapping techniques to provide a comprehensive analysis of the output, impact, and structure of the Colombian scientific elite, i.e., researchers awarded with the Alejandro Ángel Escobar Foundation National Prize 1990-2020, known locally as the Colombian Nobel. Second, we conducted a productivity and impact comparison between the Colombian scientific elite and Nobel Prize laureates in science and economics by means of a stratified random sample 1990-2020 via the composite citation indicator proposed by Ioannidis et al. Findings showed that the Colombian scientific elite has a broader agenda than indexing titles in internationally renowned bibliographic databases. The Colombian scientific elite also showed positive growth, which is an inverse trend compared with the sample of Nobel laureate productivity. There were no noticeable changes in productivity/impact before and after receiving the Alejandro Ángel Escobar Foundation National Prize. Institutional collaboration within the Colombian scientific elite displayed the highest betweenness (brokerage) role of world/local top-tier universities. However, only two Colombian scientific elite members published an article with two Nobel Prize laureates. Most of the research profiles reflected the national output priorities, but were found to diverge from the national focus in respect of strategic research capacities. The interleaving of the Colombian scientific elite and Nobel Prize laureates-particularly between the 3rd and 2nd quartiles-enabled a more nuanced analysis of the local impact in the global scientific landscape. Our findings also contrast with previous findings on the lower research impact of authors from Latin America, despite their involvement as contributors to reputable journals, and also shed light on the research performance-impact standards and agenda between the global North and South and provide an in-context assessment of outstanding local research.

Dataset Information

Ivermectin: a multifaceted drug of Nobel prize-honoured distinction with indicated efficacy against a new global scourge, COVID-19.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets